BioTek reMEDys, a multi-site national integrated infusion therapy provider focused on providing support to people with rare diseases, is publicly calling for year-round enhanced education and awareness of these rare diseases and conditions.

Autoinflammatory diseases refer to problems with the innate immune system’s reactions. Immune cells target the body’s own healthy tissues by mistake, signaling the body to attack them. This can cause intense episodes of inflammation that result in such symptoms as fever, rash, or joint swelling. These diseases also carry the risk of amyloidosis, a potentially fatal buildup of a blood protein in vital organs. Autoinflammatory diseases are typically caused by changes in certain genes. This causes problems with proteins that are important in specific body functions.

Last August was International Autoinflammatory Awareness Month, and BioTek reMEDys has been urging its colleagues, patients, and the population at large to become more aware and help drive education regarding these conditions, year-round.

BioTek reMEDys continues to be vested in the local Rare Disease community. The company’s Chief Pharmacy Officer, Andrew Babb PharmD, CSP, IgCP, was nominated and selected for the inaugural Delaware Rare Disease Advisory Council (RDAC), established by Senate Bill 55 from the 152st General Assembly, and housed within the Lieutenant Governor’s Office. The Council is an advisory body comprised of community advocates, healthcare professionals, scientists, and state leaders that works to educate medical professionals, government agencies, legislators, and the public about rare diseases as an important public health issue and encourage and secure funding for research for the development of new treatments for rare diseases.

“Auto-inflammatory conditions and rare disease at large present such a tremendous challenge for patients, their families, caregivers, and healthcare providers,” said Babb. “Information, support, and guidance can be scarce which only exacerbates the stress these patients feel. At BioTek reMEDys, we are committed to fostering awareness and will continue to advocate for the Rare Disease Community at a local and national level.”

“Because many autoimmune conditions are statistically rare, they can often be misdiagnosed,” said Chai Gadde, CEO and founder of BioTek reMEDys. “As an infusion therapy provider organization focused on the highly specific needs of patients living with rare conditions, we hope to help shine a light on the importance of education about these conditions. Treatments for autoinflammatory diseases are typically very effective and can involve medications that reduce inflammation or suppress the immune system to alleviate symptoms.”

By servicing very specific disease states such as autoinflammatory conditions, BioTek reMEDys’ expert team can maintain its focus on patient care – making sure that dosages and treatments are appropriate.

Additional information and news about autoinflammatory diseases can be found at the Autoinflammatory Alliance; NORD (National Organization for Rare Disorders); CRMO Foundation; and the International Society of Systemic Auto-inflammatory Diseases (ISSAID) website, issaid.org.

BioTek reMEDys is a multi-site national integrated infusion therapy provider focused on providing support to people with rare diseases. Through supply chain management, innovative technology and trained specialty pharmacists, BioTek reMEDys is able to deliver superior service at a lower cost. The company bridges the gap between managed care, physicians and patients by facilitating the authorization, procurement and administration of specialty medications and infusions. BioTek reMEDys provides high-touch therapies, biologics and pharmaceuticals to support treatment for patients with rare diseases and chronic conditions, ensuring the highest quality of care. For information visit www.biotekrx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251014089361/en/